|
[Related PubMed/MEDLINE]
Total Number of Papers: 214
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: tPSA |
| Long Form |
: total prostate-specific antigen |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer. |
AISI, AUC, csPCa, DCA, PI-RADS, PV, ROC |
| 2 |
2023 |
Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study. |
APT, AUC, AUC, DCE, DWI, fPSA, MRI, PSA, PSAD, ROC, T2WI |
| 3 |
2023 |
Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study. |
BMI, BPH, BPH group, fPSA, HoLEP, IPSS, PI, PV, PVR, QoL |
| 4 |
2023 |
Robot-assisted radical resection in prostate cancer comparative assessment with conventional laparoscopic prostatectomy: a retrospective comparative cohort study with single-center experience. |
BMI, DVRS, LS |
| 5 |
2022 |
Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality. |
--- |
| 6 |
2022 |
Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. |
ctDNA, HRR, mCRPC, PALB2 |
| 7 |
2022 |
Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer. |
fPSA, IL-6, PCa, ROC, UA |
| 8 |
2022 |
FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial. |
BMI, BPH, fPSA, IGF-1, WC |
| 9 |
2022 |
Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from Somalia. |
IPC, ISUP, OP, TURP |
| 10 |
2022 |
Potential factors of cytokeratin fragment 21-1 and cancer embryonic antigen for mediastinal lymph node metastasis in lung cancer. |
AFP, ALP, CEA, Hb, NSE, ROC |
| 11 |
2022 |
Predictive value of PSA density in the diagnosis of prostate cancer in lebanese men. |
PSAD |
| 12 |
2022 |
Prevalence of skeletal-related events in hormone-naive prostate cancer in a low resource setting. |
CI, GS, LUTS, OR, SREs |
| 13 |
2022 |
Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community. |
GS |
| 14 |
2022 |
Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion. |
ADC, DCE, DWI, GS, IDC-P, mpMRI, PAC, PCa, ROC-AUC |
| 15 |
2022 |
Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. |
ALP, ESR, fPSA, PCa |
| 16 |
2022 |
Risk factors of bone metastasis in patients with newly diagnosed prostate cancer. |
ALP, BMT, BMT, ECT, None-BMT, PCa, PCBM, PSAD |
| 17 |
2022 |
Survival Analysis and a Novel Nomogram Model for Progression-Free Survival in Patients with Prostate Cancer. |
ALP, PCa, PFS |
| 18 |
2022 |
The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. |
AUC, CA199, CEA, NSCLC, NSE, ProGRP, SCC-Ag |
| 19 |
2022 |
Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals. |
FBG |
| 20 |
2022 |
Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies. |
AUC, CI, LASSO, PBs, PCa, TRUS, US |
| 21 |
2022 |
[Microfocal prostate cancer: a clinicopathological analysis of 206 cases]. |
EPE, fPSA |
| 22 |
2021 |
A Large Number of Fresh Samples and a Wide Range of Total Prostate-Specific Antigen (tPSA) Concentrations Is Important to Detect Differences in PSA Methods. |
--- |
| 23 |
2021 |
Based on biomedical index data: Risk prediction model for prostate cancer. |
APOE, OR, ROC, TG |
| 24 |
2021 |
Cardiac, Hepatic and Renal Dysfunction and IL-18 Polymorphism in Breast, Colorectal, and Prostate Cancer Patients. |
ALP, ARMS, AST, CA15-3, CA19-9, CEA, CK-MB, CRC, hs-cTnT, IL, MI, OR, PCa |
| 25 |
2021 |
Effect of Combining Traditional Chinese Medicine with Hormonal Therapy on Quality of Life and Tumor Markers of Prostate Cancer Patients. |
FACT-P, fPSA, TCM |
| 26 |
2021 |
Efficacy and Prognostic Factors of Androgen Deprivation Therapy Combined with Radiation Therapy for Prostate Cancer. |
ADT, mPFS, OS, VEGF |
| 27 |
2021 |
Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study. |
AUC, BPD, csPCa, DRE, GS, mpMRI, NPV, PCa, PET/CT, PPV, ROC |
| 28 |
2021 |
Retrospective observation of the efficacy and safety of prostatic artery embolization combined with transurethral resection of the prostate and simple transurethral resection of the prostate in the treatment of large (> 100mL) benign prostatic hyperplasia. |
BL, BPH, fPSA, IPSS, OT, PAE, PBFT, PCRT, PV, PVR, QoL, SEL, TURP |
| 29 |
2021 |
The influence of age on prostate cancer screening index. |
AUC, AVR, fPSA, PCa, PSAD, ROC |
| 30 |
2020 |
Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer. |
AUC, bpMRI, CTZV, DCAs, EPE, PCa, SVI, TRUS |
| 31 |
2020 |
Analysis of Prostate-Specific Antigen-Related Indexes, Neutrophil-to-Lymphocyte Ratio in Patients with Concurrent Benign Prostatic Hyperplasia and Histologic Prostatitis. |
BPH, fPSA, NLR, tPSAD |
| 32 |
2020 |
Assessment of Serum Tumor Markers for Predicting Ocular Metastasis in Lung Adenocarcinoma: A Retrospective Study. |
AFP, CEA, OM |
| 33 |
2020 |
Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. |
BPH |
| 34 |
2020 |
Can continuous positive airway pressure improve lower urinary tract symptoms and erectile dysfunction in male patients with severe obstructive sleep apnea syndrome? |
CPAP, IPSS, OSAS |
| 35 |
2020 |
Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. |
AUC, BPH, miRNAs, PCa, ROC |
| 36 |
2020 |
Clinical value of prostate-specific antigen combined with tumor abnormal protein (TAP) in the diagnosis of prostate puncture. |
fPSA, TAP |
| 37 |
2020 |
Correlation between prostate-specific antigen and four renal function-associated parameters in different ethnicities in southwest China. |
--- |
| 38 |
2020 |
DNA Nanofirecrackers Assembled through Hybridization Chain Reaction for Ultrasensitive SERS Immunoassay of Prostate Specific Antigen. |
AA, AAP, C-HCR, SA-ALP, SERS |
| 39 |
2020 |
Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases. |
FRET, PMMA, SEM, XRD |
| 40 |
2020 |
Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA. |
NOM, NSE, OM, ROC |
| 41 |
2020 |
Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. |
AUC, fPSA, PCa, PHI, PHID, PV |
| 42 |
2020 |
Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer. |
GGG, IDC-P, PCa, PI-RADSv2 |
| 43 |
2020 |
Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy. |
PSA |
| 44 |
2020 |
The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer. |
CA125, CA153, CA199, CEA, CYFRA21-1, NSE |
| 45 |
2020 |
The importance of PSA-Density in active surveillance for prostate cancer. |
AS, PCa, PSAD |
| 46 |
2020 |
[Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer]. |
AUC, fPSA, PCa, PHI, ROC |
| 47 |
2020 |
[Relationship of prostate volume and inflammatory cell infiltration with the positive rate of prostate biopsy]. |
BMI, ICI, PSAD |
| 48 |
2020 |
[Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model]. |
F/T, PCa, ROC, ROI |
| 49 |
2019 |
Comparing clinical parameters of abnormal and normal fasting blood glucose in benign prostatic hyperplasia patients. |
BPH, FBG, HR-T2DM, IFG, IPSS, PV |
| 50 |
2019 |
Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. |
NPV, PCa, PPV, ROC |
| 51 |
2019 |
Establishing a prediction model for prostate cancer bone metastasis. |
ALP, bGS, BM, fPSA, PCa |
| 52 |
2019 |
Family history is significantly associated with prostate cancer and its early onset in Chinese population. |
BRCA, FH, PCa, RR |
| 53 |
2019 |
Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume. |
mpMRI, PCa, PI-RADSv2, PSA-AV, PSAD |
| 54 |
2019 |
p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study. |
RALP, RP |
| 55 |
2019 |
Prostate health index is useful for prostate cancer detecting in Chinese people. |
AUC, fPSA, PCa, PHI |
| 56 |
2019 |
Specific Biomarkers of Prostate Cancer-Associated Ischemic Stroke: A Case-Control Study. |
AUC, CaIS, NLR, PCa, ROC |
| 57 |
2019 |
Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study. |
BoNT-A, BPH, IPSS, LUTS, PV, PVR, TURP |
| 58 |
2018 |
Application of Six Sigma for evaluating the analytical quality of tumor marker assays. |
AFP, CA125, CA153, CA199, CEA, TEa |
| 59 |
2018 |
Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. |
p2PSA, PCa, PHI |
| 60 |
2018 |
Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era. |
CA 15.3, CEA |
| 61 |
2018 |
Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. |
BPH, PCa, PEDF, VEGF |
| 62 |
2018 |
Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples. |
FDA, fPSA, hK2, iPSA |
| 63 |
2018 |
Selected landscape phage probe as selective recognition interface for sensitive total prostate-specific antigen immunosensor. |
DPV, ELISA |
| 64 |
2018 |
Sensitivity Enhancement of Forster Resonance Energy Transfer Immunoassays by Multiple Antibody Conjugation on Quantum Dots. |
Ab, FRET, QDs |
| 65 |
2018 |
Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment. |
csPCa, PCa, PI-RADSv2, PI-RIDS v2, PSAD |
| 66 |
2018 |
[Transurethral resection of prostate treatment for recurrence of a multilocular prostatic cystadenoma: a case report]. |
fPSA, IPSS, MPC, QoL, TURP |
| 67 |
2017 |
Comparison of the clinical parameters of benign prostate hyperplasia in diabetic and non diabetic patients. |
BMI, BPH, IPSS |
| 68 |
2017 |
Does Preoperative Use of Dutasteride Decrease Bleeding During Open Prostatectomy? |
Hct, Hgb, OP |
| 69 |
2017 |
Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy. |
AUC, fPSA, PCa, PHI, pT stage |
| 70 |
2017 |
Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA). |
ALP, AMPPD, CLEIA, fPSA, fPSA, HRP, PSA |
| 71 |
2017 |
Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents. |
beta-hCG, CA125, CA15-3, CK-MB, fPSA, FSH, iPTH, LH, RIs, rubella IgG |
| 72 |
2017 |
The establishment and evaluation of a new model for the prediction of prostate cancer. |
AUC, BPH, CIs, cPSA, fPSA, PCP, ROC |
| 73 |
2017 |
The role of sex steroid hormones in benign prostatic hyperplasia. |
AED, BPH, DHT, LUTS |
| 74 |
2017 |
The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score≥7 prostate cancer from group of biopsy-based Gleason score≤6. |
NLR, RP |
| 75 |
2017 |
Validation of the prostate health index in a predictive model of prostate cancer. |
fPSA, PHI |
| 76 |
2017 |
[Use of prostate health index in diagnosing prostate cancer in Chinese men]. |
AUC, PHI, ROC |
| 77 |
2016 |
Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate for prostates larger than 60gr: A retrospective study at a single academic tertiary care center. |
B-TUERP, B-TURP, IPSS, QoL, RUV, TURS |
| 78 |
2016 |
Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study. |
PCa, PHI |
| 79 |
2016 |
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. |
CI, fPSA, mCRPC, OS, PFS, PHI |
| 80 |
2016 |
Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006. |
cPSA, PCa |
| 81 |
2016 |
Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer. |
fPSA, PCa |
| 82 |
2016 |
Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. |
AUC, DRE, p2PSA, PCa, PHI, PSAD, TRUS |
| 83 |
2016 |
Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis. |
fPSA, PCa, PCP-SMART, PCRD |
| 84 |
2016 |
[Efficacy of periprostatic nerve block anesthesia for pain control in transrectal ultrasound- guided systematic prostate biopsy]. |
fPSA, PPNB, VAS |
| 85 |
2016 |
[Trends in Gleason scores of Chinese prostate carcinoma from 1995 to 2014]. |
GS, NB, PCa, RP, TURP |
| 86 |
2015 |
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. |
fPSA, MSMB, ProtecT |
| 87 |
2015 |
High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients. |
DRE, PCa, PCA3, PHI |
| 88 |
2015 |
Perioperative prostate specific antigen levels among coronary artery bypass grafting patients: Does extracorporeal circulation and body temperature induce prostate specific antigen levels alterations? |
CABG, ECC |
| 89 |
2015 |
Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making. |
--- |
| 90 |
2015 |
Status of External Quality Assessment on Tumor Markers in China. |
AFP, CA125, CA15-3, CA19-9, CEA, CV, EQA |
| 91 |
2015 |
The place of prostate rebiopsy in the diagnosis of prostate cancer. |
ASAP, DRE, HGPIN, IHC, PB, PCa, TRUS |
| 92 |
2015 |
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment]. |
fPSA, mCRPC, PSA, SPECT |
| 93 |
2015 |
[Case-control studies of the relevant factors among Ningxia Hui and Han prostate cancer groups]. |
ARP, FBG, fPSA, TC, TG |
| 94 |
2014 |
A prospective controlled study to determine the duration of antibiotherapy in the patients with elevated serum PSA levels. |
--- |
| 95 |
2014 |
Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. |
--- |
| 96 |
2014 |
Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. |
AUC, AUC, fPSA, p2PSA, p2PSA, PCa, PHI |
| 97 |
2014 |
Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. |
AUC, DCA, fPSA, p2PSA, p2PSA, PCa, PHI |
| 98 |
2014 |
Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. |
DRE, LUTS, PCa, TRUS |
| 99 |
2014 |
[Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer]. |
AUR, BPH, HP, MFR, PCa, PSAD |
| 100 |
2014 |
[Reproductive hormone levels and relevant parameters in middle-aged and older men in the urban area of Nanjing]. |
fT, SHBG, TT |
|
A Search Service for Abbreviation / Long Form
